Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-18T03:07:58.654Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of depression in an adolescent with cardiomyopathy and arrhythmia

Published online by Cambridge University Press:  17 November 2014

Canan Tanidir ,
Ibrahim C. Tanidir  and
Volkan Tuzcu
Canan Tanidir*
Affiliation:
Department of Child and Adolescent Psychiatry, Child and Adolescent Psychiatry Clinic, Bakirkoy State Hospital for Mental Health and Neurological Disorders, Istanbul, Turkey
Ibrahim C. Tanidir
Affiliation:
Department of Pediatric Cardiology, Istanbul Mehmet Akif Ersoy, Thoracic and Cardiovascular Surgery Center and Research Hospital, Istanbul, Turkey
Volkan Tuzcu
Affiliation:
Department of Pediatric Cardiology and Electrophysiology, Pediatric and Genetic Arrhythmia Center, Istanbul Medipol University Hospital, Istanbul, Turkey
*
Correspondence to: Dr I. C. Tanidir, MD, Department of Pediatric Cardiology, İstanbul Mehmet Akif Ersoy Eğitim Araştırma Hastanesi, İstasyon Mah.Turgut Özal Bulvarı No:11 Küçükçekmece- İstanbul. Tel: +90 212 692 2000; Fax: +90 212 471 9494; E-mail: cansaran@yahoo.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Patients with cardiomyopathy have a higher incidence of mood and anxiety disorders, resulting in greater probability for hospitalisation and increased risk for arrhythmia and death. We report a case of a 16-year-old boy with Danon disease, Wolff–Parkinson–White syndrome, and hypertrophic cardiomyopathy, who later developed depression and significant weight loss. The patient was successfully treated for his anxiety and depression with mirtazapine without any adverse cardiac effects.

Keywords

ArrhythmiaDanon diseasedepressionhypertrophic cardiomyopathymirtazapine
Type
Brief Reports
Information
Cardiology in the Young , Volume 25 , Issue 7 , October 2015 , pp. 1418 - 1420
Check for updates
Copyright
© Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Wang, Q, Hay, M, Clarke, D, Menahem, S. The prevalence and predictors of anxiety and depression in adolescents with heart disease. J Pediatr 2012; 161: 943–946.CrossRefGoogle ScholarPubMed
2. Hamang, A, Eide, GE, Rokne, B, Nordin, K, Oyen, N. General anxiety, depression, and physical health in relation to symptoms of heart-focused anxiety – a cross sectional study among patients living with the risk of serious arrhythmias and sudden cardiac death. Health Qual Life Outcomes 2011; 9: 100.CrossRefGoogle ScholarPubMed
3. Menteer, J, Beas, VN, Chang, JC, Reed, K, Gold, JI. Mood and health-related quality of life among pediatric patients with heart failure. Pediatr Cardiol 2013; 34: 431–437.CrossRefGoogle ScholarPubMed
4. Harris, J, Heil, JS. Managing depression in patients with advanced heart failure awaiting transplantation. Am J Health Syst Pharm 2013; 70: 867–873.CrossRefGoogle ScholarPubMed
5. Miani, D, Taylor, M, Mestroni, L, et al. Sudden death associated with danon disease in women. Am J Cardiol 2012; 109: 406–411.CrossRefGoogle ScholarPubMed
6. Boucek, D, Jirikowic, J, Taylor, M. Natural history of Danon disease. Genet Med 2011; 13: 563–568.CrossRefGoogle ScholarPubMed
7. Wan, DD, Kundhur, D, Solomons, K, Yatham, LN, Lam, RW. Mirtazapine for treatment-resistant depression: a preliminary report. J Psychiatry Neurosci 2003; 28: 55–59.Google ScholarPubMed
8. Waring, WS, Graham, A, Gray, J, Wilson, AD, Howell, C, Bateman, DN. Evaluation of a QT nomogram for risk assessment after antidepressant overdose. Br J Clin Pharmacol 2010; 70: 881–885.CrossRefGoogle ScholarPubMed
9. Leonard, CE, Bilker, WB, Newcomb, C, Kimmel, SE, Hennessy, S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 2011; 20: 903–913.CrossRefGoogle ScholarPubMed